The development of sleep/wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice.
EEG
EMG
NREM sleep
REM sleep
narcolepsy
sleep
sleep disorder
spectral analysis
subcutaneous temperature
wakefulness
Journal
Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084
Informations de publication
Date de publication:
12 12 2022
12 12 2022
Historique:
received:
12
10
2021
revised:
23
12
2021
pubmed:
20
2
2022
medline:
15
12
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
Narcolepsy Type 1 (NT1), a sleep disorder with similar prevalence in both sexes, is thought to be due to loss of the hypocretin/orexin (Hcrt) neurons. Several transgenic strains have been created to model this disorder and are increasingly being used for preclinical drug development and basic science studies, yet most studies have solely used male mice. We compared the development of narcoleptic symptomatology in male vs. female orexin-tTA; TetO-DTA mice, a model in which Hcrt neuron degeneration can be initiated by removal of doxycycline (DOX) from the diet. EEG, EMG, subcutaneous temperature, gross motor activity, and video recordings were conducted for 24-h at baseline and 1, 2, 4, and 6 weeks after DOX removal. Female DTA mice exhibited cataplexy, the pathognomonic symptom of NT1, by Week 1 in the DOX(-) condition but cataplexy was not consistently present in males until Week 2. By Week 2, both sexes showed an impaired ability to sustain long wake bouts during the active period, the murine equivalent of excessive daytime sleepiness in NT1. Subcutaneous temperature appeared to be regulated at lower levels in both sexes as the Hcrt neurons degenerated. During degeneration, both sexes also exhibited the "Delta State", characterized by sudden cessation of activity, high delta activity in the EEG, maintenance of muscle tone and posture, and the absence of phasic EMG activity. Since the phenotypes of the two sexes were indistinguishable by Week 6, we conclude that both sexes can be safely combined in future studies to reduce cost and animal use.
Identifiants
pubmed: 35182424
pii: 6532492
doi: 10.1093/sleep/zsac039
pmc: PMC9742901
pii:
doi:
Substances chimiques
Orexins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : R01 NS098813
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS103529
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11371-6
pubmed: 9736743
Sleep. 1983;6(2):137-46
pubmed: 6878983
Psychopharmacology (Berl). 2021 Jun;238(6):1495-1511
pubmed: 33550481
J Neurosci. 2009 Nov 18;29(46):14423-38
pubmed: 19923277
J Neurosci. 2011 Nov 9;31(45):16107-16
pubmed: 22072663
Front Neurosci. 2019 Mar 18;13:207
pubmed: 30936820
Neurology. 2002 Jun 25;58(12):1826-33
pubmed: 12084885
PLoS One. 2012;7(3):e32799
pubmed: 22479340
Front Neurosci. 2021 Mar 04;15:644757
pubmed: 33746708
Behav Brain Res. 2016 Jul 15;308:205-10
pubmed: 27118715
Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R533-40
pubmed: 16556901
Sleep. 2021 Apr 9;44(4):
pubmed: 33220057
Sleep Med. 2014 May;15(5):502-7
pubmed: 24780133
J Physiol. 2010 Nov 1;588(Pt 21):4117-29
pubmed: 20807795
Neuropharmacology. 2016 Nov;110(Pt A):268-276
pubmed: 27474349
Sleep. 2013 Sep 01;36(9):1391-404
pubmed: 23997373
J Neurosci. 2014 May 7;34(19):6495-509
pubmed: 24806676
Sleep. 2021 Jun 11;44(6):
pubmed: 33313880
Biol Psychiatry. 2017 Nov 1;82(9):623-633
pubmed: 27919403
Elife. 2020 Apr 21;9:
pubmed: 32314734
Sleep. 2002 Mar 15;25(2):197-202
pubmed: 11902429
J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1354-7
pubmed: 18653548
J Sleep Res. 2005 Dec;14(4):437-45
pubmed: 16364145
Sleep. 2006 Sep;29(9):1224-31
pubmed: 17040010
Proc Natl Acad Sci U S A. 2017 May 30;114(22):5731-5736
pubmed: 28507129
Neurobiol Sleep Circadian Rhythms. 2021 Jun 13;11:100068
pubmed: 34195482
Brain Sci. 2020 Dec 30;11(1):
pubmed: 33396736
J Neurosci. 2011 Apr 20;31(16):6028-40
pubmed: 21508228
J Neurosci. 2014 May 7;34(19):6485-94
pubmed: 24806675
CNS Drugs. 2020 Jan;34(1):9-27
pubmed: 31953791
Sleep. 2021 Sep 13;44(9):
pubmed: 33720375
Acta Neurol Scand. 2009 Oct;120(4):276-80
pubmed: 19456307
Nat Rev Neurol. 2019 Sep;15(9):519-539
pubmed: 31324898
Sleep Med Rev. 2019 Feb;43:23-36
pubmed: 30503715
J Sleep Res. 2013 Oct;22(5):482-95
pubmed: 23496005
Alcohol Clin Exp Res. 2018 Mar;42(3):540-550
pubmed: 29265376
PLoS One. 2013 May 01;8(5):e62205
pubmed: 23658713
Sleep. 2007 Jan;30(1):13-26
pubmed: 17310860
J Sleep Res. 2016 Jun;25(3):356-64
pubmed: 26809504
N Engl J Med. 2015 Dec 31;373(27):2654-62
pubmed: 26716917
Sleep. 2006 Nov;29(11):1444-9
pubmed: 17162991
Sleep Med. 2009 Apr;10(4):422-6
pubmed: 19013100
Sleep Med. 2004 Jan;5(1):37-41
pubmed: 14725825
Sleep. 2003 May 1;26(3):267-72
pubmed: 12749544
J Womens Health (Larchmt). 2018 Apr;27(4):525-530
pubmed: 29356591
Sleep Med. 2020 Apr;68:97-109
pubmed: 32032921
Sleep. 2009 Jan;32(1):111-6
pubmed: 19189786
J Clin Sleep Med. 2017 Mar 15;13(3):419-425
pubmed: 27923434
Sleep. 2006 Sep;29(9):1211-23
pubmed: 17040009
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7118-23
pubmed: 16636276
Exp Neurol. 2009 May;217(1):46-54
pubmed: 19416673
ILAR J. 2002;43(4):244-58
pubmed: 12391400
Sleep. 2019 Jul 8;42(7):
pubmed: 31004158